Radicle Revive 24: A Study of Health and Wellness Products on Hormonal Health and Associated Health Outcomes in Women With Peri-Menopausal Health Issues

Eligibility Criteria

• * Adults, at least 40 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities
• * Assigned sex at birth is female
• * Resides in the United States
• * Identifies menstrual status as perimenopausal
• * Has the opportunity for at least 30% improvement in their primary health outcome
• * Indicates having peri-menopausal issues for 3 months or longer
• * Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
• * Individuals who report any of the following during screening will be excluded from participation:
• * Reports being pregnant or breastfeeding
• * Unable to provide a valid US shipping address and mobile phone number
• * Reports current enrollment in another clinical trial
• * Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
• * Unable to read and understand English
• * Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk.
• * Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients.
• * NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure
• * Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.
• * Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products
• * Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) that may limit the effects of the study products and/or pose a safety risk to participants
• * Reports an allergy to and/or disinterest in any of the possible study product ingredients
• * Lack of reliable daily access to the internet